Cancer is a genetic disease, which is induced by the accumulation of harmful DNA mutations in cells. At present, the mechanisms of inducing abnormal cell proliferation, differentiation and cancer production are mainly studied in three categories: activating dominant transforming proto-oncogenes by translocations and mutations, inactivating tumor suppressor gene by mutations, and disordering the DNA repair genes. There are 2 basic types of genetic mutations:
Germline mutations. Genetic changes that promote cancer can be inherited from our parents. If a germline mutation occurs in a sperm cell or egg cell, it may pass from generation to generation. Cancer caused by germline mutations is called inherited cancer. Researches show that, it accounts for about 5% to 20% of all cancers.
Somatic mutations. These are the most common cause of cancer. They occur from damage to genes in a particular cell during one’s lifetime, which then go on to divide many times and form a tumor. And these mutations are not found in every cell in the body and they are not passed from parent to child. Cancer that occurs because of somatic (or acquired) mutations is called sporadic cancer.
Mutations happen often. A mutation may be beneficial, harmful, or neutral. This depends where in the gene the change occurs. In general, cancer cells have more genetic changes than normal cells. But each person’s cancer has a unique combination of genetic alterations. As the cancer continues to grow, additional changes will occur. Even within the same tumor, cancer cells may have different genetic changes.
CD Genomics' provides different kinds of Ready-To-Use NGS cancer panels for cancer related researches. CD Genomics’ Ready-To-Use NGS cancer panels utilizes targeted NGS sequencing technology to provide more efficient and accurate targeting of specific genes or mutations, and even to detect low frequency variations in cancer-associated genes. Targeted NGS sequencing facilitates sequencing of a large number of genes and samples in a single and cost-effective assay.
|Cat. No.||Product Name||Brief Description||Inquiry||Basket|
|PN108||CDAMP® ctDNA 50 Panel Kit||Designed for target enrichment and library preparation using a fast and simple workflow, in next generation sequencing (NGS) applications on Illumina platforms. Based on UMI technology, low-frequency variants below 0.1% allele frequency can be detected.|
|PN203||CD NGS Targeted Hotspot Panel||CD NGS Targeted Hotspot Panel is a comprehensive pan-cancer assay designed to detect clinically relevant hotspot mutations in solid tumors.|
|PN204||CD RNA Fusion Gene Panel||CD RNA Fusion Gene Panel is a complete RNA-to-analysis solution that detects known fusion genes with as little as 10 ng of input RNA.|
|PN206||CD BRCA Complete Expanded Panel||CD BRCA Complete Expanded Panel is a complete NGS solution from DNA to interpreting sequencing data that detects germline and somatic mutations with comprehensive coverage, specificity and high sensitivity.|